Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 295

1.

Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.

Iovieno N, Papakostas GI.

J Clin Psychiatry. 2012 Oct;73(10):1300-6. doi: 10.4088/JCP.11r07485. Review.

PMID:
23140647
3.

Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.

Freeman MP, Mischoulon D, Tedeschini E, Goodness T, Cohen LS, Fava M, Papakostas GI.

J Clin Psychiatry. 2010 Jun;71(6):682-8. doi: 10.4088/JCP.10r05976blu.

PMID:
20573327
4.

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.

Khin NA, Chen YF, Yang Y, Yang P, Laughren TP.

J Clin Psychiatry. 2011 Apr;72(4):464-72. doi: 10.4088/JCP.10m06191. Erratum in: J Clin Psychiatry. 2011 Jun;72(6):874.

PMID:
21527123
5.

Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials.

Tedeschini E, Levkovitz Y, Iovieno N, Ameral VE, Nelson JC, Papakostas GI.

J Clin Psychiatry. 2011 Dec;72(12):1660-8. doi: 10.4088/JCP.10r06531.

PMID:
22244025
6.

Antidepressants for major depressive disorder and dysthymic disorder in patients with comorbid alcohol use disorders: a meta-analysis of placebo-controlled randomized trials.

Iovieno N, Tedeschini E, Bentley KH, Evins AE, Papakostas GI.

J Clin Psychiatry. 2011 Aug;72(8):1144-51. doi: 10.4088/JCP.10m06217. Epub 2011 Apr 19.

PMID:
21536001
7.

Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.

Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN.

CNS Spectr. 2009 Apr;14(4):197-206.

PMID:
19407731
8.

Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctôt KL.

J Clin Psychiatry. 2010 Mar;71(3):270-9. doi: 10.4088/JCP.08r04516blu. Epub 2010 Jan 26. Review.

PMID:
20122371
9.

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Papakostas GI, Fava M.

Eur Neuropsychopharmacol. 2009 Jan;19(1):34-40. doi: 10.1016/j.euroneuro.2008.08.009. Epub 2008 Sep 26. Review.

PMID:
18823760
10.

Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.

Tedeschini E, Fava M, Papakostas GI.

J Clin Psychiatry. 2011 Jan;72(1):98-113. doi: 10.4088/JCP.09m05725blu. Epub 2010 Nov 2. Review.

PMID:
21208576
11.

A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder.

Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M.

J Clin Psychopharmacol. 2006 Feb;26(1):56-60.

PMID:
16415707
12.

Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.

Papakostas GI, Martinson MA, Fava M, Iovieno N.

J Clin Psychiatry. 2016 May;77(5):e619-24. doi: 10.4088/JCP.14r09767.

PMID:
27249092
13.

Sponsorship, antidepressant dose, and outcome in major depressive disorder: meta-analysis of randomized controlled trials.

Sinyor M, Schaffer A, Smart KA, Levitt AJ, Lanctôt KL, Grysman NH.

J Clin Psychiatry. 2012 Feb;73(2):e277-87. doi: 10.4088/JCP.11r07204.

PMID:
22401489
14.
16.

Antidepressants for major depressive disorder in patients with a co-morbid axis-III disorder: a meta-analysis of patient characteristics and placebo response rates in randomized controlled trials.

Iovieno N, Tedeschini E, Ameral VE, Rigatelli M, Papakostas GI.

Int Clin Psychopharmacol. 2011 Mar;26(2):69-74. doi: 10.1097/YIC.0b013e328340775e. Review.

PMID:
20962663
17.

Meta-analysis of placebo rates in major depressive disorder trials.

Stolk P, Ten Berg MJ, Hemels ME, Einarson TR.

Ann Pharmacother. 2003 Dec;37(12):1891-9.

PMID:
14632596
18.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
19.

Treatment of major depressive disorder and dysthymic disorder with antidepressants in patients with comorbid opiate use disorders enrolled in methadone maintenance therapy: a meta-analysis.

Pedrelli P, Iovieno N, Vitali M, Tedeschini E, Bentley KH, Papakostas GI.

J Clin Psychopharmacol. 2011 Oct;31(5):582-6. doi: 10.1097/JCP.0b013e31822c0adf.

PMID:
21869696
20.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628

Supplemental Content

Support Center